Management of Stage III Melanoma

Source: OncLive, July 2019

Transcript:

Jeffrey S. Weber, MD, PhD: Melanoma is the deadliest form of skin cancer, but unprecedented advances in immunotherapy and targeted agents have led to safer and more effective ways to treat this disease. Today I’m joined by a panel of experts in melanoma to delve into the latest studies, including the most exciting data from the 2019 ASCO [American Society of Clinical Oncology] Annual Meeting. Together, we will provide perspective on how these data can be applied to real-world scenarios and how to individualize treatment strategies for your patients. I’m Dr Jeffrey Weber. I’m the deputy director of the Laura and Isaac Perlmutter Cancer Center and a codirector of the Melanoma Research Program at NYU [Langone Health] in New York City.

Today I’m joined by my colleagues: Dr Jason Luke, the director of the Center for Immunotherapeutics and an associate professor of medicine in hematology-oncology at the University of Pittsburgh Medical Center and the Hillman Cancer Center in Pittsburgh, Pennsylvania; and Dr Vernon Sondak, who’s the chair of the Department of Cutaneous Oncology at the Moffitt Cancer Center in Tampa, Florida, and a professor in the Department of Oncologic Sciences at the University of South Florida in Tampa, Florida. We also have Dr Ryan Sullivan, who’s an assistant professor of medicine at Harvard Medical School and who works as an oncologist at Massachusetts General Hospital in Boston, Massachusetts. And finally, we have Dr Hussein Tawbi, an associate professor in the Department of Melanoma Medical Oncology and [the] director of Melanoma Clinical Research and Early Drug Development at The University of Texas MD Anderson Cancer Center in Houston, Texas.